305 related articles for article (PubMed ID: 12449722)
1. Expression of c-myc and bcl-2 in primary and advanced cutaneous melanoma.
Utikal J; Leiter U; Udart M; Kaskel P; Peter RU; Krähn GM
Cancer Invest; 2002; 20(7-8):914-21. PubMed ID: 12449722
[TBL] [Abstract][Full Text] [Related]
2. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma.
Leiter U; Schmid RM; Kaskel P; Peter RU; Krähn G
Arch Dermatol Res; 2000 May; 292(5):225-32. PubMed ID: 10867810
[TBL] [Abstract][Full Text] [Related]
3. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
Gradilone A; Gazzaniga P; Ribuffo D; Scarpa S; Cigna E; Vasaturo F; Bottoni U; Innocenzi D; Calvieri S; Scuderi N; Frati L; Aglianò AM
J Clin Oncol; 2003 Jan; 21(2):306-12. PubMed ID: 12525523
[TBL] [Abstract][Full Text] [Related]
4. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.
Chana JS; Wilson GD; Cree IA; Alexander RA; Myatt N; Neale M; Foss AJ; Hungerford JL
Br J Ophthalmol; 1999 Jan; 83(1):110-4. PubMed ID: 10209447
[TBL] [Abstract][Full Text] [Related]
5. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases.
Kraehn GM; Utikal J; Udart M; Greulich KM; Bezold G; Kaskel P; Leiter U; Peter RU
Br J Cancer; 2001 Jan; 84(1):72-9. PubMed ID: 11139316
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
7. Different patterns of cell proliferation and death and oncogene expression in cutaneous malignant melanoma.
Miracco C; Santopietro R; Biagioli M; Lazzi S; Nyongo A; Vatti R; Luzi P
J Cutan Pathol; 1998 May; 25(5):244-51. PubMed ID: 9696289
[TBL] [Abstract][Full Text] [Related]
8. bcl-2 protein expression in melanocytic neoplasms of the skin.
Ramsay JA; From L; Kahn HJ
Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma.
Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC
Am J Pathol; 1995 Mar; 146(3):643-50. PubMed ID: 7534042
[TBL] [Abstract][Full Text] [Related]
10. Intercellular adhesion molecule 1 (ICAM-1) and bcl-2 are differentially expressed in early evolving malignant melanoma.
Collins KA; White WL
Am J Dermatopathol; 1995 Oct; 17(5):429-38. PubMed ID: 8599446
[TBL] [Abstract][Full Text] [Related]
11. C-myc overexpression drives melanoma metastasis by promoting vasculogenic mimicry via c-myc/snail/Bax signaling.
Lin X; Sun R; Zhao X; Zhu D; Zhao X; Gu Q; Dong X; Zhang D; Zhang Y; Li Y; Sun B
J Mol Med (Berl); 2017 Jan; 95(1):53-67. PubMed ID: 27543492
[TBL] [Abstract][Full Text] [Related]
12. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
13. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
[TBL] [Abstract][Full Text] [Related]
14. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
15. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi.
Cerroni L; Soyer HP; Kerl H
Am J Dermatopathol; 1995 Feb; 17(1):7-11. PubMed ID: 7695015
[TBL] [Abstract][Full Text] [Related]
16. c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression.
Jiang X; Tsang YH; Yu Q
Int J Biochem Cell Biol; 2007; 39(5):1016-25. PubMed ID: 17331788
[TBL] [Abstract][Full Text] [Related]
17. miR-211 and MITF modulation by Bcl-2 protein in melanoma cells.
De Luca T; Pelosi A; Trisciuoglio D; D'Aguanno S; Desideri M; Farini V; Di Martile M; Bellei B; Tupone MG; Candiloro A; Regazzo G; Rizzo MG; Del Bufalo D
Mol Carcinog; 2016 Dec; 55(12):2304-2312. PubMed ID: 26599548
[TBL] [Abstract][Full Text] [Related]
18. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi.
Saenz-Santamaría MC; Reed JA; McNutt NS; Shea CR
J Cutan Pathol; 1994 Oct; 21(5):393-7. PubMed ID: 7868749
[TBL] [Abstract][Full Text] [Related]
20. Expression of apoptosis regulators in cutaneous malignant melanoma.
Tang L; Tron VA; Reed JC; Mah KJ; Krajewska M; Li G; Zhou X; Ho VC; Trotter MJ
Clin Cancer Res; 1998 Aug; 4(8):1865-71. PubMed ID: 9717813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
